Pietro Palmisano, Zefferino Palamà, Antonio L Bartorelli, Salvatore Bonanno, Giuseppe Tricarico, Pasquale Crea, Giovanni Coluccia
{"title":"高功率短时间房颤消融后症状性肺静脉狭窄的风险。","authors":"Pietro Palmisano, Zefferino Palamà, Antonio L Bartorelli, Salvatore Bonanno, Giuseppe Tricarico, Pasquale Crea, Giovanni Coluccia","doi":"10.1111/pace.70040","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Symptomatic pulmonary vein stenosis (sPVS) is a rare but severe complication of transcatheter atrial fibrillation (AF) ablation. High-power, short-duration (HPSD) and very HPSD (vHPSD) approaches for radiofrequency (RF) AF ablation have been shown to improve procedural efficiency, with effectiveness and a short-term safety profile comparable to conventional standard-power long-duration (SPLD) ablation. Findings from some previous reports suggest that HPSD may be a risk factor for the development of sPVS. The aim of this multicenter, observational analysis was to compare the incidence of sPVS after AF ablation with HPSD, vHPSD, and SPLD.</p><p><strong>Methods: </strong>Data from 436 consecutive patients (63.1 ± 9.5 years, 66.5% male, 70.9% with paroxysmal AF) undergoing RF AF ablation were reviewed: 64 were ablated with HPSD, 71 with vHPSD, and 301 with SPLD. The incidence of sPVS during follow-up was assessed.</p><p><strong>Results: </strong>There were no significant differences in baseline characteristics between the three groups. During a median follow-up of 20 months, 9 cases of sPVS were identified: 7 (10.9%) in HPSD group, 1 (1.4%) in vHPSD group, and 1 (0.3%) in SPLD group (p < 0.001). The use of HPSD approach was an independent predictor of sPVS (hazard ratio, 20.226; 95% confidence interval, 20.49-164.59; p = 0.005) on multivariable analysis. Seven of 9 patients underwent percutaneous PVs angioplasty and stent implantation (3 veins in 4 patients, 2 veins in 2 patients, 1 vein in 1 patient).</p><p><strong>Conclusions: </strong>The results of this observational analysis suggest that RF AF ablation using HPSD approach may be associated with an increased risk of sPVS.</p>","PeriodicalId":520740,"journal":{"name":"Pacing and clinical electrophysiology : PACE","volume":" ","pages":"1191-1195"},"PeriodicalIF":1.3000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Risk of Symptomatic Pulmonary Vein Stenosis After Atrial Fibrillation Ablation With High-Power Short-Duration Approach.\",\"authors\":\"Pietro Palmisano, Zefferino Palamà, Antonio L Bartorelli, Salvatore Bonanno, Giuseppe Tricarico, Pasquale Crea, Giovanni Coluccia\",\"doi\":\"10.1111/pace.70040\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Symptomatic pulmonary vein stenosis (sPVS) is a rare but severe complication of transcatheter atrial fibrillation (AF) ablation. High-power, short-duration (HPSD) and very HPSD (vHPSD) approaches for radiofrequency (RF) AF ablation have been shown to improve procedural efficiency, with effectiveness and a short-term safety profile comparable to conventional standard-power long-duration (SPLD) ablation. Findings from some previous reports suggest that HPSD may be a risk factor for the development of sPVS. The aim of this multicenter, observational analysis was to compare the incidence of sPVS after AF ablation with HPSD, vHPSD, and SPLD.</p><p><strong>Methods: </strong>Data from 436 consecutive patients (63.1 ± 9.5 years, 66.5% male, 70.9% with paroxysmal AF) undergoing RF AF ablation were reviewed: 64 were ablated with HPSD, 71 with vHPSD, and 301 with SPLD. The incidence of sPVS during follow-up was assessed.</p><p><strong>Results: </strong>There were no significant differences in baseline characteristics between the three groups. During a median follow-up of 20 months, 9 cases of sPVS were identified: 7 (10.9%) in HPSD group, 1 (1.4%) in vHPSD group, and 1 (0.3%) in SPLD group (p < 0.001). The use of HPSD approach was an independent predictor of sPVS (hazard ratio, 20.226; 95% confidence interval, 20.49-164.59; p = 0.005) on multivariable analysis. Seven of 9 patients underwent percutaneous PVs angioplasty and stent implantation (3 veins in 4 patients, 2 veins in 2 patients, 1 vein in 1 patient).</p><p><strong>Conclusions: </strong>The results of this observational analysis suggest that RF AF ablation using HPSD approach may be associated with an increased risk of sPVS.</p>\",\"PeriodicalId\":520740,\"journal\":{\"name\":\"Pacing and clinical electrophysiology : PACE\",\"volume\":\" \",\"pages\":\"1191-1195\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pacing and clinical electrophysiology : PACE\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1111/pace.70040\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pacing and clinical electrophysiology : PACE","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/pace.70040","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/11 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Risk of Symptomatic Pulmonary Vein Stenosis After Atrial Fibrillation Ablation With High-Power Short-Duration Approach.
Background: Symptomatic pulmonary vein stenosis (sPVS) is a rare but severe complication of transcatheter atrial fibrillation (AF) ablation. High-power, short-duration (HPSD) and very HPSD (vHPSD) approaches for radiofrequency (RF) AF ablation have been shown to improve procedural efficiency, with effectiveness and a short-term safety profile comparable to conventional standard-power long-duration (SPLD) ablation. Findings from some previous reports suggest that HPSD may be a risk factor for the development of sPVS. The aim of this multicenter, observational analysis was to compare the incidence of sPVS after AF ablation with HPSD, vHPSD, and SPLD.
Methods: Data from 436 consecutive patients (63.1 ± 9.5 years, 66.5% male, 70.9% with paroxysmal AF) undergoing RF AF ablation were reviewed: 64 were ablated with HPSD, 71 with vHPSD, and 301 with SPLD. The incidence of sPVS during follow-up was assessed.
Results: There were no significant differences in baseline characteristics between the three groups. During a median follow-up of 20 months, 9 cases of sPVS were identified: 7 (10.9%) in HPSD group, 1 (1.4%) in vHPSD group, and 1 (0.3%) in SPLD group (p < 0.001). The use of HPSD approach was an independent predictor of sPVS (hazard ratio, 20.226; 95% confidence interval, 20.49-164.59; p = 0.005) on multivariable analysis. Seven of 9 patients underwent percutaneous PVs angioplasty and stent implantation (3 veins in 4 patients, 2 veins in 2 patients, 1 vein in 1 patient).
Conclusions: The results of this observational analysis suggest that RF AF ablation using HPSD approach may be associated with an increased risk of sPVS.